BerGenBio

Pre-Annual General Meeting Information • Apr 28, 2023

BERGENBIO ASA: Notice of Annual General Meeting

BERGENBIO ASA: Notice of Annual General Meeting

Bergen, Norway - 28 April 2023: BerGenBio ASA (OSE:BGBIO) will be holding its

Annual General Meeting virtually on 22 May 2022 at 16:00 hours (CEST).

The notice, registration form, power of attorney and proposal from Nomination

Committee are attached to this release. The notice will be sent to all

registered shareholders and is available on the Company's website:

https://www.bergenbio.com/investors/general-meetings/

All shareholders are encouraged to exercise their shareholder rights, either

through advance electronically voting through VPS Investor Services, by using

the enclosed proxy form to provide proxy to the Chairman Anders Tullgren (or the

person he appoints), or to attend the general meeting virtually.

Advance vote or proxy for the Annual General Meeting can be registered through

the company's website (https://www.bergenbio.com/investors/general-meetings/) or

VPS Investor

Service (https://investor.vps.no/gm/logOn.htm?token=0dcfac4c9479467293d057ff7858a

f59b30f3819&validTo=1687356000000&oppdragsId=20230424VPQ54GU0) within 9 May 2023

16:00 hours (CEST). Virtual participants need to be logged in to the meeting

before 16:00 hours (CEST) 22 May 2023.

All shareholders will receive a reference number and a pin code required for

registration through the company's website. Reference number and pin code will

be received either by VPS Investor Service or by post depending if the

shareholder is registered as electronical user.

We encourage all shareholders to register as electronical user in VPS.

- END -

AboutBerGenBioASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including cancer and severe respiratory infections. The

Company is focused on its proprietary lead candidate bemcentinib a potentially

first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC

and severe respiratory infections.

BerGenBiois based in Bergen, Norway with a subsidiary in Oxford, UK. The company

is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information,

visit?www.bergenbio.com

Contacts

Martin Olin, CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.